Viking Therapeutics, Inc. (VKTX)
About Viking Therapeutics, Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$359.6M
- Total assets
- $715.7M
- Market cap
- $4.0B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $393.3M
- Operating income
- -$393.3M
- Income tax
- $1.0K
- Net income
- -$359.6M
- EPS (basic)
- $-3.19
- EPS (diluted)
- $-3.19
Balance sheet
- Total assets
- $715.7M
- Current assets
- $715.6M
- Total liabilities
- $76.7M
- Current liabilities
- $76.7M
- Shareholders’ equity
- $639.1M
Cash flow
- Operating cash flow
- -$278.7M
- Investing cash flow
- $341.4M
- Financing cash flow
- $76.4M
- Net cash flow
- $139.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.0B
- EPS (diluted)
- $-3.19
- Shares outstanding
- 94.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 2015
Viking Therapeutics, Inc. (VKTX) Stock Price
- Reported a net loss of $359.6M in FY2025.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Viking Therapeutics, Inc..
Write a review
News about Viking Therapeutics, Inc.
News & sentiment via Polygon.io
Viking Therapeutics, Inc.: frequently asked questions
Is Viking Therapeutics, Inc. an American company?
Viking Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Viking Therapeutics, Inc. publicly traded?
Yes — Viking Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol VKTX on the NASDAQ.
What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
